Tenax Therapeutics Approves Officer Exculpation Amendment

Tenax Therapeutics ( (TENX) ) has shared an announcement.

On June 11, 2025, Tenax Therapeutics held its annual stockholders meeting, where several proposals were voted on, including the approval of an Officer Exculpation Amendment to the company’s Certificate of Incorporation, which was filed and became effective in mid-June 2025. Additionally, the stockholders elected directors, approved executive compensation, and ratified the appointment of Cherry Bekaert LLP as the company’s independent auditor for 2025.

The most recent analyst rating on (TENX) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Tenax Therapeutics stock, see the TENX Stock Forecast page.

Spark’s Take on TENX Stock

According to Spark, TipRanks’ AI Analyst, TENX is a Underperform.

Tenax Therapeutics’ overall score reflects substantial financial challenges due to an absence of revenue and consistent losses, heavily reliant on equity financing. Technical indicators suggest neutral momentum, but poor financial performance and valuation overshadow any potential stability.

To see Spark’s full report on TENX stock, click here.

More about Tenax Therapeutics

Tenax Therapeutics, Inc. operates in the biotechnology industry, focusing on developing and commercializing pharmaceutical products aimed at treating critical care and cardiovascular diseases.

Average Trading Volume: 16,465

Technical Sentiment Signal: Sell

Current Market Cap: $25.35M

For detailed information about TENX stock, go to TipRanks’ Stock Analysis page.